Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study Samantha Thifani Alrutz Barcelos; Amanda Souza Silva-Sperb; Helena Abadie Moraes; Larisse Longo; Bruna Concheski de Moura; Matheus Truccolo Michalczuk; Carolina Uribe-Cruz; Carlos Thadeu Schmidt Cerski; Themis Reverbel da Silveira; Valesca Dall'Alba; Mário Reis Álvares-da-Silva;

Antibiotic consumption, genetic risk and incidence of metabolic dysfunction-associated steatotic liver disease: a prospective cohort study Ziming Zheng; Yumei Huang; Jijuan Zhang; Jinchi Xie; An Pan; Yunfei Liao; Yu Zhang;

FLI and FIB-4 in diagnosing metabolic dysfunction-associated steatotic liver disease in primary care: High prevalence and risk of significant disease Mário Reis Álvares-da-Silva; Márcia da Silva Vargas; Soheyla Mohd Souza Rabie; Gabriella Jonko; Patricia Gabriela Riedel; Larisse Longo; Marcelo Rodrigues Gonçalves; Vivian Cristine Luft; Dvora Joveleviths;